Currently Adimmune still chiefly sells its vaccines domestically, with 2007 and 2008 sales revenues coming to NT $ 190 million and NT $ 240 million respectively. The major chunk of such vaccines-60 % to 70 % -are for seasonal flu.
目前國光疫苗仍以內銷為主，2007 與 2008 年的銷售額各為台幣 1.9 億及 2.4 億元，其中又以季節性流感為大宗，占 6 至 7 成。